An analysis of public genomic datasets revealed that high DGAT1 levels in melanoma patients were associated with worse progression-free survival 21, as was also shown using the glioblastoma multiforme (GBM) dataset 22. This evidence concerns the gene DGAT1 and glioblastoma.